Bexarotene nanocrystal - Oral and parenteral formulation development, characterization and pharmacokinetic evaluation

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 87, Issue 1, 2014, Pages 160-169

  Chen, Lijiang ^a,b   Wang, Yongjie ^b   Zhang, Jiaozhen ^a   Hao, Leilei ^a   Guo, Hejian ^a   Lou, Hongxiang ^a   Zhang, Dianrui ^a  

^a SHANDONG UNIVERSITY   (China)

^b LIAONING UNIVERSITY   (China)

Author keywords

Bexarotene; Crystalline state; Dissolution rate; Nanocrystals; Parenteral administration; Pharmacokinetics

Indexed keywords

BEXAROTENE; NANOCRYSTAL; RETINOID; RETINOID X RECEPTOR; ANTINEOPLASTIC AGENT; DRUG CARRIER; NANOPARTICLE; TETRALIN DERIVATIVE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MICROFLUIDICS; MORPHOLOGY; MOUSE; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRECIPITATION; RAMAN SPECTROMETRY; RAT; TRANSMISSION ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION; ZETA POTENTIAL; AGONISTS; ANIMAL; BLOOD; CHEMISTRY; FREEZE DRYING; ORAL DRUG ADMINISTRATION; SOLUBILITY; SURFACE PROPERTY; TISSUE DISTRIBUTION; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG LIBERATION; FREEZE DRYING; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; RATS, WISTAR; RETINOID X RECEPTORS; SOLUBILITY; SPECTRUM ANALYSIS, RAMAN; SURFACE PROPERTIES; TETRAHYDRONAPHTHALENES; TISSUE DISTRIBUTION;

EID: 84901587804     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.12.005     Document Type: Article

References (53)

1. M.M. Yallapu, M. Jaggi, and S.C. Chauhan Curcumin nanoformulations: a future nanomedicine for cancer Drug Discov. Today 17 2012 71 80
2. M.T. Crisp, C.J. Tucker, T.L. Rogers, R.O. Williams, and K.P. Johnston Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals J. Control. Release 117 2007 351 359 (Pubitemid 46216578)
3. R. Harding, L. Selman, G. Agupio, N. Dinat, J. Downing, L. Gwyther, T. Mashao, K. Mmoledi, L.M. Sebuyira, B. Ikin, and I.J. Higginson The prevalence and burden of symptoms amongst cancer patients attending palliative care in two African countries Eur. J. Cancer 47 2011 51 56
4. T.W. Hermann, W.-C. Yen, P. Tooker, B. Fan, K. Roegner, A. Negro-Vilar, W.W. Lamph, and R.P. Bissonnette The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells Lung Cancer 50 2005 9 18 (Pubitemid 41297464)
5. S.M. Malik, B. Collins, M. Pishvaian, P. Ramzi, J. Marshall, and J. Hwang A phase I trial of bexarotene in combination with docetaxel in patients with advanced solid tumors Clin. Lung Cancer 12 2011 231 236
6. N. Mehta, A.S. Wayne, Y.H. Kim, G.A. Hale, C.S. Alvarado, P. Myskowski, E.S. Jaffe, K.J. Busam, M. Pulitzer, J. Zwerner, and S. Horwitz Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations Clin. Lymphoma Myeloma Leukemia 12 2012 20 25
7. W.C. Yen A selective retinoid X receptor agonist bexarotene (targretin) prevents and overcomes acquired paclitaxel (taxol) resistance in human non-small cell lung cancer Clin. Cancer Res. 10 2004 8656 8664
8. Q. Zhang, J. Pan, J. Zhang, P. Liu, R. Chen, D.r. Chen, R. Lubet, Y. Wang, and M. You Aerosolized bexarotene inhibits lung tumorigenesis without increasing plasma triglyceride and cholesterol levels in mice Cancer Prevent. Res. 4 2010 270 276
9. Y. Li, Y. Zhang, J. Hill, H.T. Kim, Q. Shen, R.P. Bissonnette, W.W. Lamph, and P.H. Brown The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice Br. J. Cancer 98 2008 1380 1388 (Pubitemid 351543584)
10. A.A. Thorat, and S.V. Dalvi Liquid antisolvent precipitation and stabilization of nanoparticles of poorly water soluble drugs in aqueous suspensions: recent developments and future perspective Chem. Eng. J. 181-182 2012 1 34
11. H. Chen, C. Khemtong, X. Yang, X. Chang, and J. Gao Nanonization strategies for poorly water-soluble drugs Drug Discov. Today 16 2011 354 360
12. Q. Fu, L. Kou, C. Gong, M. Li, J. Sun, D. Zhang, M. Liu, X. Sui, K. Liu, S. Wang, and Z. He Relationship between dissolution and bioavailability for nimodipine colloidal dispersions: the critical size in improving bioavailability Int. J. Pharm. 427 2012 358 364
13. L. Gao, G. Liu, J. Ma, X. Wang, L. Zhou, and X. Li Drug nanocrystals: in vivo performances J. Control. Release 160 2012 418 430
14. S. Branchu, P.G. Rogueda, A.P. Plumb, and W.G. Cook A decision-support tool for the formulation of orally active, poorly soluble compounds Eur. J. Pharm. Sci. 32 2007 128 139 (Pubitemid 47299301)
15. K. Kawakami Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs Adv. Drug Deliv. Rev. 64 2012 480 495
16. X. Lin, X. Li, L. Zheng, L. Yu, Q. Zhang, and W. Liu Preparation and characterization of monocaprate nanostructured lipid carriers Colloids Surf. A 311 2007 106 111 (Pubitemid 350026290)
17. R.H. Müller, R. Shegokar, and C.M. Keck 20 Years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications Curr. Drug Discov. Technol. 8 2011 207 227
18. R.H. Müller, R. Shegokar, S. Gohla, and C.M. Keck Nanocrystals: production, cellular drug delivery, current and future products Intracellular Deliv. 5 2011 411 432
19. H.S.M. Ali, P. York, A.M.A. Ali, and N. Blagden Hydrocortisone nanosuspensions for ophthalmic delivery: a comparative study between microfluidic nanoprecipitation and wet milling J. Control. Release 149 2011 175 181
20. W.H. Roa, S. Azarmi, M.H.D.K. Al-Hallak, W.H. Finlay, A.M. Magliocco, and R. Löbenberg Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model J. Control. Release 150 2011 49 55
21. Müller. Junghanns Nanocrystal technology, drug delivery and clinical applications Int. J. Nanomed. 3 2008 295 309
22. L. Yao, X. Zhao, Q. Li, Y. Zu, Y. Fu, B. Zu, X. Meng, and C. Liu In vitro and in vivo evaluation of camptothecin nanosuspension: a novel formulation with high antitumor efficacy and low toxicity Int. J. Pharm. 423 2012 586 588
23. R.H. Müller, S. Gohla, and C.M. Keck State of the art of nanocrystals - special features, production, nanotoxicology aspects and intracellular delivery Eur. J. Pharm. Biopharm. 78 2011 1 9
24. Y. Kawabata, K. Wada, M. Nakatani, S. Yamada, and S. Onoue Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications Int. J. Pharm. 420 2011 1 10
25. R.H.H. Neubert Potentials of new nanocarriers for dermal and transdermal drug delivery Eur. J. Pharm. Biopharm. 77 2011 1 2
26. G. Cevc, and U. Vierl Nanotechnology and the transdermal routeA state of the art review and critical appraisal J. Control. Release 141 2010 277 299
27. S. Das, and P.K. Suresh Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B Nanomed. Nanotechnol. Biol. Med. 7 2011 242 247
28. J. Zhang, L. Wu, H.-K. Chan, and W. Watanabe Formation, characterization, and fate of inhaled drug nanoparticles Adv. Drug Deliv. Rev. 63 2011 441 455
29. C. Keck, and R. Muller Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation Eur. J. Pharm. Biopharm. 62 2006 3 16 (Pubitemid 41736019)
30. A. Elgart, I. Cherniakov, Y. Aldouby, A.J. Domb, and A. Hoffman Lipospheres and pro-nano lipospheres for delivery of poorly water soluble compounds Chem. Phys. Lipids 165 2012 438 453
31. J.M. Irache, I. Esparza, C. Gamazo, M. Agüeros, and S. Espuelas Nanomedicine: novel approaches in human and veterinary therapeutics Vet. Parasitol. 180 2011 47 71
32. B. Van Eerdenbrugh, G. Van den Mooter, and P. Augustijns Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products Int. J. Pharm. 364 2008 64 75
33. R.H. Müller, and C.M. Keck Twenty years of drug nanocrystals: where are we, and where do we go? Eur. J. Pharm. Biopharm. 80 2012 1 3
34. B.E. Rabinow Nanosuspensions in drug delivery Nat. Rev. Drug Discov. 3 2004 785 796 (Pubitemid 39242830)
35. J. Hu, W.K. Ng, Y. Dong, S. Shen, and R.B.H. Tan Continuous and scalable process for water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent precipitation and spray-drying Int. J. Pharm. 404 2011 198 204
36. S. Verma, S. Kumar, R. Gokhale, and D.J. Burgess Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening Int. J. Pharm. 406 2011 145 152
37. S. Verma, R. Gokhale, and D.J. Burgess A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions Int. J. Pharm. 380 2009 216 222
38. M. Juhnke, D. Märtin, and E. John Generation of wear during the production of drug nanosuspensions by wet media milling Eur. J. Pharm. Biopharm. 81 2012 214 222
39. J. Salazar, A. Ghanem, R.H. Müller, and J.P. Möschwitzer Nanocrystals: comparison of the size reduction effectiveness of a novel combinative method with conventional top-down approaches Eur. J. Pharm. Biopharm. 81 2012 82 90
40. M. Kakran, R. Shegokar, N.G. Sahoo, L. Al Shaal, L. Li, and R.H. Müller Fabrication of quercetin nanocrystals: comparison of different methods Eur. J. Pharm. Biopharm. 80 2012 113 121
41. Y. Liu, D. Zhang, D. Zou, Y. Wang, C. Duan, L. Jia, P. Xie, F. Feng, F. Wang, X. Zhang, and Q. Zhang Development and in vitro characterizations of bifendate nanosuspensions J. Biomed. Nanotechnol. 7 2011 621 631
42. W. Sun, W. Tian, Y. Zhang, J. He, S. Mao, and L. Fang Effect of novel stabilizers - cationic polymers on the particle size and physical stability of poorly soluble drug nanocrystals Nanomed. Nanotechnol. Biol. Med. 8 2012 460 467
43. L. Hao, X. Wang, D. Zhang, Q. Xu, S. Song, F. Wang, C. Li, H. Guo, Y. Liu, D. Zheng, and Q. Zhang Studies on the preparation, characterization and pharmacokinetics of Amoitone B nanocrystals Int. J. Pharm. 433 2012 157 164
44. J. Zhang, H. Lv, K. Jiang, and Y. Gao Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal Int. J. Pharm. 420 2011 180 188
45. Y. Wang, Z. Liu, D. Zhang, X. Gao, X. Zhang, C. Duan, L. Jia, F. Feng, Y. Huang, Y. Shen, and Q. Zhang Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension Colloids Surf. B 83 2011 189 197
46. G. Liu, D. Zhang, Y. Jiao, D. Zheng, Y. Liu, C. Duan, L. Jia, Q. Zhang, and H. Lou Comparison of different methods for preparation of a stable riccardin D formulation via nano-technology Int. J. Pharm. 422 2012 516 522
47. W. Yancai, Z. Dianrui, L. Zhaoping, L. Guangpu, D. Cunxian, J. Lejiao, F. Feifei, Z. Xiaoyu, S. Yanqiu, and Z. Qiang In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery Nanotechnology 21 2010 155104
48. L. Gao, G. Liu, X. Wang, F. Liu, Y. Xu, and J. Ma Preparation of a chemically stable quercetin formulation using nanosuspension technology Int. J. Pharm. 404 2011 231 237
49. F. Kesisoglou, S. Panmai, and Y. Wu Nanosizing - oral formulation development and biopharmaceutical evaluation Adv. Drug Deliv. Rev. 59 2007 631 644 (Pubitemid 47285408)
50. Y. Gao, Z. Li, M. Sun, H. Li, C. Guo, J. Cui, A. Li, F. Cao, Y. Xi, H. Lou, and G. Zhai Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer Drug Develop. Ind. Pharm. 36 2010 1225 1234
51. L. Wu, J. Zhang, and W. Watanabe Physical and chemical stability of drug nanoparticles Adv. Drug Deliv. Rev. 63 2011 456 469
52. K. Sigfridsson, S. Forssén, P. Hollände r, U. Skantze, and J. de Verdier A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound Eur. J. Pharm. Biopharm. 67 2007 540 547 (Pubitemid 47225040)
53. S. Yalkowsky, J. Krzyzaniak, and G. Ward Formulation-related problems associated with intravenous drug delivery J. Pharm. Sci. 87 1998 787 796 (Pubitemid 28319406)